Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 473213, 5 pages
http://dx.doi.org/10.1155/2014/473213
Research Article

Effects of Danshen Ethanol Extract on the Pharmacokinetics of Fexofenadine in Healthy Volunteers

Laboratory of Clinical Pharmacokinetics, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received 12 June 2014; Accepted 30 August 2014; Published 3 November 2014

Academic Editor: Min Ye

Copyright © 2014 Furong Qiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Giacomini, S.-M. Huang, D. J. Tweedie et al., “Membrane transporters in drug development,” Nature Reviews Drug Discovery, vol. 9, no. 3, pp. 215–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. O. Cheng, “Danshen: A popular chinese cardiac herbal drug,” Journal of the American College of Cardiology, vol. 47, no. 7, pp. 1498–1500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Y. Xu, R. Z. Wan, Y. P. Lin, L. Yang, Y. Chen, and C. X. Liu, “Recent advance on research and application of Salvia miltiorrhiza,” Asian Journal of Drug Metabolism and Pharmacokinetics, vol. 7, pp. 99–130, 2007. View at Google Scholar
  4. X. Y. Ji, B. K. H. Tan, and Y. Z. Zhu, “Salvia miltiorrhiza and ischemic diseases,” Acta Pharmacologica Sinica, vol. 21, no. 12, pp. 1089–1094, 2000. View at Google Scholar · View at Scopus
  5. M. Song, T.-J. Hang, Z. Zhang, and H.-Y. Chen, “Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat,” European Journal of Pharmaceutical Sciences, vol. 32, no. 4-5, pp. 247–253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Qiu, J. Jiang, Y. Ma et al., “Opposite effects of single-dose and multidose administration of the ethanol extract of danshen on CYP3A in healthy volunteers,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 730734, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Yu, S. Ye, H. Sun et al., “PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA,” Chemico-Biological Interactions, vol. 177, no. 1, pp. 58–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Geick, M. Eichelbaum, and O. Burk, “Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin,” Journal of Biological Chemistry, vol. 276, no. 18, pp. 14581–14587, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Perloff, L. L. von Moltke, and D. J. Greenblatt, “Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir,” Journal of Clinical Pharmacology, vol. 42, no. 11, pp. 1269–1274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Drescher, E. Schaeffeler, M. Hitzl et al., “MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine,” British Journal of Clinical Pharmacology, vol. 53, no. 5, pp. 526–534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Zhou, Z. Ye, Z. Ruan, and S. Zeng, “Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe,” Journal of Ethnopharmacology, vol. 146, no. 3, pp. 744–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Garrett, J. Smeraglia, X. Lin, and L. Tan, “A pilot study to assess simultaneous administration of oral midazolam (MDZ) and fexofenadine (FEX) for the evaluation of cytochrome (CYP) 3A4 and P-glycoprotein (P-GP) activities,” Clinical Pharmacology & Therapeutics, vol. 77, p. 45, 2005. View at Google Scholar
  13. M. Shimizu, T. Uno, K. Sugawara, and T. Tateishi, “Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein,” British Journal of Clinical Pharmacology, vol. 62, no. 3, pp. 372–376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. P. G. van Heeswijk, M. Bourbeau, P. Campbell et al., “Time-dependent interaction between lopinavir/ritonavir and fexofenadine,” Journal of Clinical Pharmacology, vol. 46, no. 7, pp. 758–767, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Sakugawa, M. Miura, N. Hokama, T. Suzuki, T. Tateishi, and T. Uno, “Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil,” British Journal of Clinical Pharmacology, vol. 67, no. 5, pp. 535–540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Akamine, M. Miura, N. Yasui-Furukori, M. Kojima, and T. Uno, “Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers,” The British Journal of Clinical Pharmacology, vol. 73, no. 3, pp. 478–481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Hamman, M. A. Bruce, B. D. Haehner-Daniels, and S. D. Hall, “The effect of rifampin administration on the disposition of fexofenadine,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 114–121, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Wang, M. A. Hamman, S.-M. Huang, L. J. Lesko, and S. D. Hall, “Effect of St John's wort on the pharmacokenetics of fexofenadine,” Clinical Pharmacology and Therapeutics, vol. 71, no. 6, pp. 414–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Shimizu, K. Fuse, K. Okudaira et al., “ontribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans,” Drug Metabolism and Disposition, vol. 33, no. 10, pp. 1477–1481, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Nishimura, S. Naito, and T. Yokoi, “Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies,” Drug Metabolism and Pharmacokinetics, vol. 19, no. 2, pp. 135–149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Nishimura and S. Naito, “Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies,” Drug Metabolism and Pharmacokinetics, vol. 20, no. 6, pp. 452–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Williamson, K. E. Dooley, Y. Zhang, D. J. Back, and A. Owen, “Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 12, pp. 6366–6369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Pal and A. K. Mitra, “MDR- and CYP3A4-mediated drug-herbal interactions,” Life Sciences, vol. 78, no. 18, pp. 2131–2145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. K. Dresser, U. I. Schwarz, G. R. Wilkinson, and R. B. Kim, “Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects,” Clinical Pharmacology and Therapeutics, vol. 73, no. 1, pp. 41–50, 2003. View at Publisher · View at Google Scholar · View at Scopus